Business Context and Reporting Period
This Form 8-K is a current report filed by Xcyte Therapies, Inc. on May 13, 2004. The filing serves to announce the company's financial results for the first quarter ended March 31, 2004. The report incorporates a press release (Exhibit 99.1) by reference but explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text provided does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text. Consequently, no financial metrics can be extracted from this document alone.
Material Changes
The filing does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of a press release announcing the Q1 2004 results.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The content is limited to the administrative notification of the press release and the incorporation of that exhibit by reference.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as the 8-K text itself lacks these numbers.
- Confirm the company's current operational status and cash runway, given the filing is from 2004 and the company may have undergone significant changes since then.
- Check for any subsequent filings or updates regarding the Q1 2004 results if the press release contained preliminary or unaudited figures.